Completion Of The First Batch Of Subject Enrollment For The Phase I Clinical Trial Of The Company’s Novel Adjuvanted Recombinant Shingles Vaccine REC610

PR Newswire
February 13, 2023 — 15:02 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: China Covid-19 finance healthcare Hong Kong investment jiangsu Joint venture medicine stock exchange technology Vaccine

Related News:

AVAPOW’s Black Friday Event: Essential Automotive Tools At Exclusive Prices

November 22, 2024 — 04:00

Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

November 8, 2024 — 17:45

New features revealed for PaperCut Hive cloud print management solution

November 8, 2024 — 06:32

LPS Launches NeuroNode: Empowering Advanced AI for Enterprises with On-Premises LLM

November 7, 2024 — 17:39

Cybellum Receives Frost & Sullivan’s Competitive Strategy Award for its Innovative Product Security Solutions

September 27, 2024 — 01:00

Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation

September 14, 2024 — 08:18

Desay Battery Highlights Advanced Energy Solutions at RE+ 2024

September 11, 2024 — 03:00

Announcement of ICAIRE’s Classification as a UNESCO Category 2 Center at the Global AI Summit

September 11, 2024 — 02:34

Transcenta Holding Limited (Stock Code: 6628.HK) Announce 2024 Interim Results

August 29, 2024 — 14:31

Franchising and Licensing Asia (FLAsia) 2024